Back to top
more

Chemed (CHE)

(Real Time Quote from BATS)

$425.49 USD

425.49
40,025

+7.64 (1.83%)

Updated Aug 4, 2025 11:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Chemed (CHE) Q2 Earnings Miss Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of -10.67% and +0.45%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ASTH vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

ASTH vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Analysts Estimate Chemed (CHE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ASTH or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ASTH vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Reasons to Add Align Technology Stock to Your Portfolio Now

by Zacks Equity Research

ALGN's Invisalign growth, iTero innovation and solid finances fuel optimism despite forex headwinds.

Zacks Equity Research

AMED or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMED vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Chemed (CHE) Up 2.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

OPCH vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

OPCH vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

CHE Stock Falls Despite Q1 Earnings & Revenue Beat, Gross Margin Declines

by Zacks Equity Research

Chemed delivers first-quarter top-line growth across two of its segments, VITAS and Roto-Rooter.

Zacks Equity Research

Chemed (CHE) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 0.54% and 1.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OPCH or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

OPCH vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Why Is Chemed (CHE) Up 4.5% Since Last Earnings Report?

by Zacks Equity Research

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

OPCH vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

OPCH vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

OPCH or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

OPCH vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Chemed Q4 Earnings & Revenues Top, Stock Climbs, Margins Contract

by Zacks Equity Research

CHE's earnings and revenues beat estimates in the fourth quarter of 2024.

Zacks Equity Research

Chemed (CHE) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 0.59% and 1.78%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) Q4 Earnings Miss Estimates

by Zacks Equity Research

Elanco Animal Health (ELAN) delivered earnings and revenue surprises of -6.67% and 0.83%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ADUS vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

ADUS vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Should Investors Hold Chemed Stock in Their Portfolio Now?

by Zacks Equity Research

CHE stays on investors' radar due to its robust prospects in the VITAS business and the resilient Roto-Rooter arm.

Zacks Equity Research

EHC vs. CHE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EHC vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

EHC or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EHC vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Amedisys (AMED) Down 12.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

EHC vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

EHC vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Chemed Stock Hurt by Roto-Rooter Softness, Macro Issues Dent Growth

by Zacks Equity Research

The ongoing global economic conditions, such as general labor, supply chain and inflationary pressure, along with political and regulatory developments, are escalating expenses for CHE.

Zacks Equity Research

AMED or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMED vs. CHE: Which Stock Is the Better Value Option?